Research units on pediatric psychopharmacology (RUPP) Autism Network

Background and rationale for an initial controlled study of risperidone

C. J. McDougle, L. Scahill, J. T. McCracken, M. G. Aman, E. Tierney, L. E. Arnold, B. J. Freeman, A. Martin, J. J. McGough, P. Cronin, D. J. Posey, M. A. Riddle, L. Ritz, Naomi Swiezy, B. Vitiello, F. R. Volkmar, N. A. Votolato, P. Walson

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network. Risperidone has potent effects on 5-HT and DA neuronal systems, both of which have been implicated in the pathophysiology of autism. Unlike the typical antipsychotics, haloperidol and pimozide, which have been shown to be effective for reducing many of the maladaptive behaviors associated with autism, risperidone's 5-HT2(A)/DA D2 ratio of receptor blockade appears to produce a lower risk of acute and chronic extrapyramidal side effects, as well as enhanced efficacy for the 'negative' symptoms of autism. Indirect clinical and preclinical evidence supports the use of risperidone to treat impaired social behavior, interfering repetitive phenomena, and aggression, targets of pharmacotherapy for many patients with autism. Numerous published open-label trials in children and adolescents with autism and related PDDs and one double-blind, placebo-controlled study in adults suggest that risperidone has promise for the treatment of children and adolescents with autism. Because most of these studies have been short-term, open-label trials in small samples, however, a large-scale controlled study of risperidone in children and adolescents with autism is needed to confirm these results. Finally, because it is likely that children who demonstrate short-term benefit from risperidone will remain on the medication indefinitely, the longer-term effectiveness and safety of risperidone in this population also needs to be determined. The design of this study and the assessments used are described separately.

Original languageEnglish
Pages (from-to)201-224
Number of pages24
JournalChild and Adolescent Psychiatric Clinics of North America
Volume9
Issue number1
StatePublished - 2000

Fingerprint

Psychopharmacology
Risperidone
Autistic Disorder
Pediatrics
Research
Pimozide
Social Behavior
Haloperidol
Aggression
Antipsychotic Agents
Serotonin
Placebos
Safety
Drug Therapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health

Cite this

Research units on pediatric psychopharmacology (RUPP) Autism Network : Background and rationale for an initial controlled study of risperidone. / McDougle, C. J.; Scahill, L.; McCracken, J. T.; Aman, M. G.; Tierney, E.; Arnold, L. E.; Freeman, B. J.; Martin, A.; McGough, J. J.; Cronin, P.; Posey, D. J.; Riddle, M. A.; Ritz, L.; Swiezy, Naomi; Vitiello, B.; Volkmar, F. R.; Votolato, N. A.; Walson, P.

In: Child and Adolescent Psychiatric Clinics of North America, Vol. 9, No. 1, 2000, p. 201-224.

Research output: Contribution to journalArticle

McDougle, CJ, Scahill, L, McCracken, JT, Aman, MG, Tierney, E, Arnold, LE, Freeman, BJ, Martin, A, McGough, JJ, Cronin, P, Posey, DJ, Riddle, MA, Ritz, L, Swiezy, N, Vitiello, B, Volkmar, FR, Votolato, NA & Walson, P 2000, 'Research units on pediatric psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone', Child and Adolescent Psychiatric Clinics of North America, vol. 9, no. 1, pp. 201-224.
McDougle, C. J. ; Scahill, L. ; McCracken, J. T. ; Aman, M. G. ; Tierney, E. ; Arnold, L. E. ; Freeman, B. J. ; Martin, A. ; McGough, J. J. ; Cronin, P. ; Posey, D. J. ; Riddle, M. A. ; Ritz, L. ; Swiezy, Naomi ; Vitiello, B. ; Volkmar, F. R. ; Votolato, N. A. ; Walson, P. / Research units on pediatric psychopharmacology (RUPP) Autism Network : Background and rationale for an initial controlled study of risperidone. In: Child and Adolescent Psychiatric Clinics of North America. 2000 ; Vol. 9, No. 1. pp. 201-224.
@article{96824a0076eb450180d15ceef9d622aa,
title = "Research units on pediatric psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone",
abstract = "This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network. Risperidone has potent effects on 5-HT and DA neuronal systems, both of which have been implicated in the pathophysiology of autism. Unlike the typical antipsychotics, haloperidol and pimozide, which have been shown to be effective for reducing many of the maladaptive behaviors associated with autism, risperidone's 5-HT2(A)/DA D2 ratio of receptor blockade appears to produce a lower risk of acute and chronic extrapyramidal side effects, as well as enhanced efficacy for the 'negative' symptoms of autism. Indirect clinical and preclinical evidence supports the use of risperidone to treat impaired social behavior, interfering repetitive phenomena, and aggression, targets of pharmacotherapy for many patients with autism. Numerous published open-label trials in children and adolescents with autism and related PDDs and one double-blind, placebo-controlled study in adults suggest that risperidone has promise for the treatment of children and adolescents with autism. Because most of these studies have been short-term, open-label trials in small samples, however, a large-scale controlled study of risperidone in children and adolescents with autism is needed to confirm these results. Finally, because it is likely that children who demonstrate short-term benefit from risperidone will remain on the medication indefinitely, the longer-term effectiveness and safety of risperidone in this population also needs to be determined. The design of this study and the assessments used are described separately.",
author = "McDougle, {C. J.} and L. Scahill and McCracken, {J. T.} and Aman, {M. G.} and E. Tierney and Arnold, {L. E.} and Freeman, {B. J.} and A. Martin and McGough, {J. J.} and P. Cronin and Posey, {D. J.} and Riddle, {M. A.} and L. Ritz and Naomi Swiezy and B. Vitiello and Volkmar, {F. R.} and Votolato, {N. A.} and P. Walson",
year = "2000",
language = "English",
volume = "9",
pages = "201--224",
journal = "Child and Adolescent Psychiatric Clinics of North America",
issn = "1056-4993",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Research units on pediatric psychopharmacology (RUPP) Autism Network

T2 - Background and rationale for an initial controlled study of risperidone

AU - McDougle, C. J.

AU - Scahill, L.

AU - McCracken, J. T.

AU - Aman, M. G.

AU - Tierney, E.

AU - Arnold, L. E.

AU - Freeman, B. J.

AU - Martin, A.

AU - McGough, J. J.

AU - Cronin, P.

AU - Posey, D. J.

AU - Riddle, M. A.

AU - Ritz, L.

AU - Swiezy, Naomi

AU - Vitiello, B.

AU - Volkmar, F. R.

AU - Votolato, N. A.

AU - Walson, P.

PY - 2000

Y1 - 2000

N2 - This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network. Risperidone has potent effects on 5-HT and DA neuronal systems, both of which have been implicated in the pathophysiology of autism. Unlike the typical antipsychotics, haloperidol and pimozide, which have been shown to be effective for reducing many of the maladaptive behaviors associated with autism, risperidone's 5-HT2(A)/DA D2 ratio of receptor blockade appears to produce a lower risk of acute and chronic extrapyramidal side effects, as well as enhanced efficacy for the 'negative' symptoms of autism. Indirect clinical and preclinical evidence supports the use of risperidone to treat impaired social behavior, interfering repetitive phenomena, and aggression, targets of pharmacotherapy for many patients with autism. Numerous published open-label trials in children and adolescents with autism and related PDDs and one double-blind, placebo-controlled study in adults suggest that risperidone has promise for the treatment of children and adolescents with autism. Because most of these studies have been short-term, open-label trials in small samples, however, a large-scale controlled study of risperidone in children and adolescents with autism is needed to confirm these results. Finally, because it is likely that children who demonstrate short-term benefit from risperidone will remain on the medication indefinitely, the longer-term effectiveness and safety of risperidone in this population also needs to be determined. The design of this study and the assessments used are described separately.

AB - This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network. Risperidone has potent effects on 5-HT and DA neuronal systems, both of which have been implicated in the pathophysiology of autism. Unlike the typical antipsychotics, haloperidol and pimozide, which have been shown to be effective for reducing many of the maladaptive behaviors associated with autism, risperidone's 5-HT2(A)/DA D2 ratio of receptor blockade appears to produce a lower risk of acute and chronic extrapyramidal side effects, as well as enhanced efficacy for the 'negative' symptoms of autism. Indirect clinical and preclinical evidence supports the use of risperidone to treat impaired social behavior, interfering repetitive phenomena, and aggression, targets of pharmacotherapy for many patients with autism. Numerous published open-label trials in children and adolescents with autism and related PDDs and one double-blind, placebo-controlled study in adults suggest that risperidone has promise for the treatment of children and adolescents with autism. Because most of these studies have been short-term, open-label trials in small samples, however, a large-scale controlled study of risperidone in children and adolescents with autism is needed to confirm these results. Finally, because it is likely that children who demonstrate short-term benefit from risperidone will remain on the medication indefinitely, the longer-term effectiveness and safety of risperidone in this population also needs to be determined. The design of this study and the assessments used are described separately.

UR - http://www.scopus.com/inward/record.url?scp=0034101344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034101344&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 201

EP - 224

JO - Child and Adolescent Psychiatric Clinics of North America

JF - Child and Adolescent Psychiatric Clinics of North America

SN - 1056-4993

IS - 1

ER -